Prescription medicine
Metyrapone Brand names: Metopirone
Metyrapone (Metopirone) is a prescription medicine with an FDA approval on record since 1961. No generic is listed in FDA's NDC Directory.
- No generic listed
Check it at the source: the metyrapone FDA label on DailyMed (effective May 19, 2026, ESTEVE PHARMACEUTICALS, S.A.); the NDA 12911 record on Drugs@FDA; every metyrapone label on DailyMed.
Highlights of the record
FDA label of May 19, 2026; NDC Directory, Drugs@FDA and Orange Book, October 8, 2026
Used for
From the label: indications and usageMetopirone is indicated, in combination with other diagnostic tests, for the diagnosis of adrenal insufficiency in adult and pediatric patients.
Forms and strengths
- 250 mg
Gelatin-coated capsule.
On the market
- Earliest approval on file
- December 4, 1961 Metopirone, Esteve; Drugs@FDA’s file, where older or withdrawn approvals can be missing
- Generic approvals
- No generic approved
- Labelers listed (NDC)
- 2 of which 0 under generic applications, 2 under brand applications, repackagers included
Supply and safety
- Pharmacy cost (NADAC)
- Not in the survey
- Shortage (FDA)
- No current entry
- Recalls by its makers (FDA)
- No recall recorded
- FAERS reports
- 977 through July 30, 2026
What is metyrapone used for?
From the label: indications and usageMetopirone is indicated, in combination with other diagnostic tests, for the diagnosis of adrenal insufficiency in adult and pediatric patients. Metopirone is indicated, in combination with other diagnostic tests, for the diagnosis of adrenal insufficiency in adult and pediatric patients.
FDA pharmacologic class: Adrenal Steroid Synthesis Inhibitor.
Source: FDA drug label (Metopirone), ESTEVE PHARMACEUTICALS, S.A., effective May 19, 2026 (SPL set 4046b167-7a46-8f4a-e063-6394a90a147f), via openFDA; the full label on DailyMed
Is there a generic for metyrapone (Metopirone)?
No generic metyrapone is approved (Drugs@FDA, October 8, 2026).
- 1961 earliest approval on file
Source: Drugs@FDA, FDA NDC Directory and the Orange Book (openFDA bulk files, October 8, 2026)
What does the metyrapone label say about other medicines?
The metyrapone label names 2 other medicines in its interaction, contraindication or warning sections. The sentences are the labels' own; a label lists what its studies and reports found, not every interaction.
| Medicine named | Section | What the label says |
|---|---|---|
| Acetaminophen | drug interactions | Metopirone on Other Drugs Acetaminophen Metopirone inhibits the glucuronidation of acetaminophen, which may decrease elimination of acetaminophen and lead to increased risk of adverse reactions related to acetaminophen. |
| Cyproheptadine | drug interactions | DRUG INTERACTIONS Anticonvulsants, psychotropic, hormone preparations, corticosteroids, antithyroid agents, cyproheptadine: may affect the results of the metyrapone test. |
Source: FDA drug label (Metopirone), ESTEVE PHARMACEUTICALS, S.A., effective May 19, 2026 (SPL set 4046b167-7a46-8f4a-e063-6394a90a147f), via openFDA; the full label on DailyMed
What do FAERS reports show for metyrapone?
The FDA Adverse Event Reporting System holds 977 reports that list metyrapone among the medicines taken, through July 30, 2026, each a report of something that happened, not proof the medicine caused it; 120 are coded as a death and 314 as a hospital stay. Counts follow how widely a medicine is used and watched, and they are not a measure of how risky it is.
Reports received each year
The most reported reactions
Source: FDA Adverse Event Reporting System (FAERS) via openFDA, reports through July 30, 2026
What next?
- Metyrapone side effects
- the label's list beside FAERS reports
- Check an interaction
- what two or more labels say about each other